209 related articles for article (PubMed ID: 2525950)
1. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
Maccubbin DL; Mace KF; Ehrke MJ; Mihich E
Cancer Res; 1989 Aug; 49(15):4216-24. PubMed ID: 2525950
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
3. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
5. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
6. Activation of nonspecific killer cells by interleukin 2-containing supernatants.
Teh HS; Yu M
J Immunol; 1983 Oct; 131(4):1827-33. PubMed ID: 6194216
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
9. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
10. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
Fujii T; Igarashi T; Kishimoto S
J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
Chow KP; Battisto JR
J Immunol; 1988 Feb; 140(4):1005-13. PubMed ID: 2963857
[TBL] [Abstract][Full Text] [Related]
12. [T-suppressors from tumor-bearing mice inhibit antitumor cytotoxic T-lymphocytes in monoculture].
Lupatov AIu; Brondz BD
Biull Eksp Biol Med; 1992 Feb; 113(2):186-7. PubMed ID: 1535235
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
15. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
16. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.
Yamamoto H; Hirayama M; Genyea C; Kaplan J
J Immunol; 1994 Apr; 152(8):3842-7. PubMed ID: 8144953
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of loss of natural killer activity in P815 ascites tumor bearing DBA/2 mice.
Saxena RK; Saxena QB; Adler WH
Nat Immun Cell Growth Regul; 1983-1984; 3(1):34-42. PubMed ID: 6235448
[TBL] [Abstract][Full Text] [Related]
19. Suppression and abrogation of suppression of induced nonspecific cytotoxicity against tumor cells.
Egawa K; Tanino T
Jpn J Exp Med; 1985 Aug; 55(4):143-53. PubMed ID: 2935654
[TBL] [Abstract][Full Text] [Related]
20. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice.
Young MR; Newby M
J Natl Cancer Inst; 1986 Dec; 77(6):1255-60. PubMed ID: 3491925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
